Valuation: Evofem Biosciences, Inc.

Market Cap 10.6L 9L 9L 8L 14.73L 10Cr 14.94L 1.01Cr 39.61L 5.08Cr 39.81L 38.94L 17Cr P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 5.55Cr 4.79Cr 4.51Cr 4.1Cr 7.71Cr 531.55Cr 7.82Cr 53Cr 21Cr 265.85Cr 21Cr 20Cr 885.51Cr EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+6.67%
1 week-2.44%
Current month+14.29%
1 month+3.90%
3 months+23.08%
6 months-11.11%
Current year-15.79%
1 week 0.01
Extreme 0.0065
0.01
1 month 0.01
Extreme 0.0065
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.25
5 years 0
Extreme 0.0008
1,826.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+6.67%-2.44%-13.04%-95.17% 10.6L
+4.26%+0.88%+75.59%+124.32% 1,09300Cr
+0.89%+4.35%+53.82%+57.17% 65TCr
+1.83%+3.53%+25.34%+72.45% 46TCr
+1.48%-0.63%+39.58%+42.82% 35TCr
+0.98%+1.21%+24.58%+39.67% 29TCr
+1.78%+1.58%+0.89%+11.36% 25TCr
+2.64%+2.65%+45.34%+62.43% 23TCr
+1.58%-1.74%-15.44%-53.33% 20TCr
+2.51%+5.65%+21.57%+89.04% 18TCr
Average +2.29%+0.84%+25.82%+35.08% 37.1TCr
Weighted average by Cap. +2.05%+1.45%+43.65%+68.82%

Financials

2024 2025
Net sales 1.94Cr 1.67Cr 1.57Cr 1.43Cr 2.69Cr 185.52Cr 2.73Cr 18Cr 7.23Cr 93Cr 7.27Cr 7.11Cr 309.07Cr 2.02Cr 1.74Cr 1.64Cr 1.49Cr 2.8Cr 193.38Cr 2.84Cr 19Cr 7.54Cr 97Cr 7.58Cr 7.41Cr 322.15Cr
Net income -88.6L -76.52L -72L -65.44L -1.23Cr -85Cr -1.25Cr -8.45Cr -3.31Cr -42Cr -3.33Cr -3.25Cr -141.42Cr 4L 3L 3L 3L 5L 3.75Cr 6L 37.27L 14.61L 1.87Cr 14.68L 14.36L 6.24Cr
Net Debt 4.58Cr 3.96Cr 3.73Cr 3.39Cr 6.37Cr 439.21Cr 6.46Cr 44Cr 17Cr 219.67Cr 17Cr 17Cr 731.68Cr 5.44Cr 4.7Cr 4.42Cr 4.02Cr 7.56Cr 521.39Cr 7.67Cr 52Cr 20Cr 260.77Cr 20Cr 20Cr 868.59Cr
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
18/26/18 $0.008000 +6.67% 89,793
17/26/17 $0.007500 -0.32% 6,21,408
14/26/14 $0.007524 -4.15% 1,03,320
13/26/13 $0.007850 +9.03% 3,44,236
12/26/12 $0.007200 -12.20% 2,16,008

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock